“…The dosimetric advantages of proton therapy for esophageal cancer have been demonstrated in comparison to 3D-CRT and IMRT in several planning studies. [109][110][111] As compared to IMRT, both the two-beam and three-beam proton therapies resulted in much better lung sparing, with median lung V5, V10, V20, and MLD reduced by 35.6%, 20.5%, 5.8%, and 5.1 Gy and 17.4%, 8.4%, 5%, and 2.9 Gy, respectively. 110 In a dosimetric comparative study between IMRT and intensity-modulated proton therapy (IMPT), IMPT spared much more of the heart, lung, liver, and spinal cord.…”